Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1516 studies found for:    "Chronic lymphocytic leukemia"
Show Display Options
RSS Create an RSS feed from your search for:
"Chronic lymphocytic leukemia"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting B Cell Repertoires in Chronic Lymphocytic Leukemia and Aging
Condition: Chronic Lymphocytic Leukemia
Intervention:
2 Completed
Has Results
Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rituximab
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Ofatumumab;   Drug: Lenalidomide
3 Recruiting A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Obinutuzumab;   Drug: Ibrutinib
4 Active, not recruiting CD3/CD28 Bead Activated T-Cells Following Chemo-Immunotherapy in Patients With Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia
Intervention: Biological: Infusion of CD3/CD28 stimulated T cells
5 Active, not recruiting Direct Measurement of Leukemic Cell Turnover (Synthesis and Removal) in Patients With Chronic Lymphocytic Leukemia (CLL) Using Deuterated Water
Condition: Chronic Lymphocytic Leukemia
Intervention:
6 Completed Bendamustine and Mitoxantrone in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: bendamustine hydrochloride;   Drug: mitoxantrone hydrochloride
7 Completed Fludarabine With or Without Cyclophosphamide in Treating Patients With Advanced Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Fludarabine plus Cyclophosphamide;   Drug: Fludarabine
8 Withdrawn HuMax-CD20 in Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia
Intervention: Drug: HuMax-CD20
9 Completed Activity & Safety Study of Lenalidomide & Rituximab as Non-chemotherapy Based Therapy on Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia
Intervention: Drug: Lenalidomida and Rituximab
10 Completed Natural Killer Cells Function in Patients With Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia
Intervention: Other: Surface expression of functional biomarkers of the NK cell
11 Completed Autologous Stem Cell Transplantation in Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia
Interventions: Procedure: Autologous stem cell transplantation;   Procedure: DHAP rescue and Autologous stem cell transplantation;   Procedure: DHAP rescue and F+C
12 Active, not recruiting Lipoprotein Lipase Expression in Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia
Intervention:
13 Terminated
Has Results
Maintenance Therapy: Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia
Intervention: Drug: Maintenance lenalidomide
14 Completed A Safety and Efficacy Trial of a Combination of Bendamustine, Rituximab and Lenalidomide in Patients With Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia
Intervention: Drug: Bendamustine, Rituximab, Lenalidomide
15 Recruiting Phase 1b Safety and Efficacy Study of TRU-016 and Rituximab, Obinutuzumab, Idelalisib, or Ibrutinib in Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia
Interventions: Biological: 20 mg/kg TRU-016 + Rituximab;   Biological: 10 mg/kg TRU-016 + Rituximab;   Biological: TRU-016 20 mg/kg + Obinutuzumab;   Biological: TRU-016 6-20 mg/kg + idelalisib + rituximab;   Biological: TRU-016 10-20 mg/kg + ibrutinib
16 Completed Ribomustin in the First Line Therapy of Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia
Interventions: Other: bendamustine;   Other: rituximab
17 Completed Bendamustine and Rituximab in Treating Patients With Previously Untreated or Relapsed Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Bendamustine;   Biological: Rituximab
18 Completed Bendamustine Hydrochloride Injection for Initial Treatment of Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Bendamustine hydrochloride injection;   Drug: Chlorambucil
19 Active, not recruiting Rapid Infusion of Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia
Intervention: Drug: Ofatumumab
20 Completed Fludarabine or Observation in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia
Intervention: Drug: Fludarabine

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.